GlassScriptPhysician profile
Nelly D Chambers
NPI 1265435143
$752.38
in general payments reported to CMS, 2019-2025
17 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $67.56 · 2020: $30.24 · 2021: $13.89 · 2022: $140 · 2023: $418 · 2024: $83.39.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $501.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $500.97 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $248.39 | 2022-2023 | Wegovy, Ozempic, Rybelsus |
| Amgen INC. | $65.85 | 2019-2023 | Otezla, Repatha |
| Dexcom, INC. | $48.70 | 2022-2024 | Dexcom G6 Transmitter |
| Bayer Healthcare Pharmaceuticals INC. | $47.53 | 2022-2023 | |
| Janssen Pharmaceuticals, INC | $46.51 | 2019-2020 | |
| Astrazeneca Pharmaceuticals LP | $38.30 | 2020-2024 | |
| Abbvie INC. | $38.11 | 2022-2023 | Linzess |
| Lilly USA, LLC | $34.90 | 2023 | Mounjaro |
| Glaxosmithkline, LLC. | $30.51 | 2023 | Arexvy, Shingrix |
| Sanofi-Aventis U.S. LLC | $24.12 | 2023 | |
| Ardelyx, INC. | $22.73 | 2023 | Ibsrela |
| Abbott Laboratories | $21.55 | 2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $20.85 | 2019 | |
| Novartis Pharmaceuticals Corporation | $19.38 | 2024 | |
| Biohaven Pharmaceutical Holding Company LTD. | $15.85 | 2022 |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Idorsia Pharmaceuticals US INC | $15.32 | 2023 | Quviviq |
| Medtronic, INC. | $13.78 | 2024 | Venaseal |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Nelly Chambers listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.